U.S. markets open in 7 hours 17 minutes

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.37+0.36 (+2.40%)
At close: 4:00PM EDT

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
United States
650 525 5535
http://www.ternspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Mr. Senthil Vel SundaramCEO & Director581.77kN/A1978
Dr. Erin Quirk M.D.Pres & Chief Medical Officer549.39kN/A1971
Dr. Weidong Zhong Ph.D.Co-Founder, Director & Chief Scientific OfficerN/AN/A1966
Dr. Mark Joseph VignolaCFO & Treasurer402.15kN/A1978
Mr. Seokho Yoon Esq.COO, Gen. Counsel & Sec.N/AN/A1978
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.

Corporate Governance

Terns Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.